MARKET

CTSO

CTSO

Cytosorbents
NASDAQ

Real-time Quotes | Nasdaq Last Sale

8.58
-0.06
-0.69%
After Hours: 9.00 +0.42 +4.90% 17:18 03/05 EST
OPEN
8.64
PREV CLOSE
8.64
HIGH
8.69
LOW
7.82
VOLUME
516.42K
TURNOVER
--
52 WEEK HIGH
11.74
52 WEEK LOW
3.600
MARKET CAP
370.45M
P/E (TTM)
-26.6377
1D
5D
1M
3M
1Y
5Y
The Week Ahead In Biotech (March 7-13): Conference Presentations And More Earnings
Biotech stocks continued to move southward in the week ended March 5, as the broader market extended its sell-off. Though light on news, the week did witness earnings releases from smaller biopharma companies, coronavirus vaccine program updates, mixed FDA...
Benzinga · 1d ago
BRIEF-B. Braun Avitum AG And Cytosorbents Corp Announce Global Co-Marketing Agreement To Promote Omni Continuous Blood Purification Platform With Cytosorb
reuters.com · 5d ago
B. Braun Avitum AG And CytoSorbents Announce Global Joint-Marketing Agreement To Promote Use Of CytoSorb With B. Braun's OMNI Platform
Joint marketing of CytoSorb® with B. Braun's newest OMNI® blood purification platform will offer greater access of this advanced treatment of deadly inflammation to critically ill patients. MELSUNGEN,
Benzinga · 5d ago
B. Braun Avitum AG and CytoSorbents Corporation Announce Global Co-Marketing Agreement to Promote the OMNI(R) Continuous Blood Purification Platform with CytoSorb(R)
Joint marketing of CytoSorb(R)with B. Braun's newest OMNI(R) blood purification platform will offer greater access of this advanced treatment of deadly inflammation to critically ill patients.
PR Newswire Europe · 5d ago
CytoSorbents to Report Fiscal 2020 Operating and Financial Results
PR Newswire · 5d ago
Global Cardiac Surgery Devices Market – 2019-2026
Feb 26, 2021 (Heraldkeepers) -- This report studies about the Global Cardiac Surgery Devices Market Overview. The heart surgeons perform cardiac surgery due...
Heraldkeepers · 02/26 19:00
CytoSorbents to Present at the Cowen 41st Annual Health Care Conference
CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announces its participat...
PR Newswire · 02/24 12:08
Extracorporeal Membrane Oxygenation (ECMO) Market Size, Opportunities, Sales Revenue, Emerging Technologies and Growth Analysis by Forecast to 2028 | Terumo Corporation, MicroPort Scientific Corporation, NIPRO Corporation, OriGen Biomedical, etc
Feb 22, 2021 (Market Insight Reports) -- According to the current analysis of Reports and Data, the global Extracorporeal Membrane Oxygenation (ECMO)...
Market Insight Reports · 02/22 16:56
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CTSO. Analyze the recent business situations of Cytosorbents through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CTSO stock price target is 14.88 with a high estimate of 17.00 and a low estimate of 13.00.
EPS
Institutional Holdings
Institutions: 160
Institutional Holdings: 18.72M
% Owned: 43.36%
Shares Outstanding: 43.18M
TypeInstitutionsShares
Increased
32
1.36M
New
27
-58.69K
Decreased
21
919.58K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Advanced Medical Equipment & Technology
+1.35%
Healthcare Equipment & Supplies
+2.13%
Key Executives
Chairman/Non-Executive Chairman/Director/Independent Director
Al Kraus
Chief Executive Officer/President/Director
Phillip Chan
Chief Financial Officer
Kathleen Bloch
Chief Operating Officer
Vincent Capponi
Director/Independent Director
Michael Bator
Independent Director
Edward Jones
Independent Director
Alan Sobel
No Data
About CTSO
CytoSorbents Corporation is a critical care focused immunotherapy company. The Company is engaged in commercializing its product, CytoSorb, which is a blood purification technology with focus in preventing or treating multiple organ failure. The Company's purification technologies are based on biocompatible, porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. The Company's CytoSorb is an extracorporeal cytokine filter and is designed to reduce the cytokine storm that causes inflammation, organ failure and death in common critical illnesses, such as sepsis, burn injury, trauma, lung injury and pancreatitis. In addition, CytoSorb is used in other inflammatory conditions, such as cardiac surgery, autoimmune disease flares, cancer, cytokine release syndrome in cancer immunotherapy and cancer cachexia.

Webull offers kinds of Cytosorbents Corp stock information, including NASDAQ:CTSO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CTSO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CTSO stock methods without spending real money on the virtual paper trading platform.